{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:10:33Z","timestamp":1767143433063,"version":"build-2238731810"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-024-00703-9","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T13:54:14Z","timestamp":1736949254000},"page":"743-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington\u2019s Disease: Data from Enroll-HD"],"prefix":"10.1007","volume":"14","author":[{"given":"Erin Furr","family":"Stimming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel O.","family":"Claassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7997-0954","authenticated-orcid":false,"given":"Ginny P.","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Klepitskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Serbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunwoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean C.","family":"Hinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Haubenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"1","key":"703_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ. Huntington\u2019s disease: a clinical review. Eur J Neurol. 2018;25(1):24\u201334.","journal-title":"Eur J Neurol"},{"key":"703_CR2","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"AC Bachoud-L\u00e9vi","year":"2019","unstructured":"Bachoud-L\u00e9vi AC, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, et al. International guidelines for the treatment of Huntington\u2019s disease. Front Neurol. 2019;10:710.","journal-title":"Front Neurol"},{"key":"703_CR3","volume-title":"A Physician\u2019s guide to the management of Huntington\u2019s disease","author":"M Nance","year":"2011","unstructured":"Nance M, Paulsen JS, Rosenblatt A, et al. A Physician\u2019s guide to the management of Huntington\u2019s disease. 3rd ed. New York: Huntington\u2019s Disease Society of America; 2011.","edition":"3"},{"issue":"7","key":"703_CR4","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/mds.29427","volume":"38","author":"A Heinzmann","year":"2023","unstructured":"Heinzmann A, Sayah S, Lejeune FX, Hahn V, Teichmann M, Monin ML, et al. Huntington\u2019s disease with small CAG repeat expansions. Mov Disord. 2023;38(7):1294\u2013306.","journal-title":"Mov Disord"},{"issue":"1","key":"703_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3233\/JHD-200429","volume":"10","author":"DG Monckton","year":"2021","unstructured":"Monckton DG. The contribution of somatic expansion of the CAG repeat to symptomatic development in Huntington\u2019s disease: a historical perspective. J Huntingtons Dis. 2021;10(1):7\u201333.","journal-title":"J Huntingtons Dis"},{"key":"703_CR6","doi-asserted-by":"crossref","unstructured":"CAG repeat not polyglutamine length determines timing of Huntington's disease onset. Cell. 2019;178(4):887\u2013900 (e14).","DOI":"10.1016\/j.cell.2019.06.036"},{"key":"703_CR7","unstructured":"Huntington\u2019s Disease Society of America. Who is at risk. 2022. https:\/\/hdsa.org\/what-is-hd\/history-and-genetics-of-huntingtons-disease\/who-is-at-risk\/. Accessed 21 Oct 2022."},{"issue":"3","key":"703_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000524732","volume":"56","author":"A Exuzides","year":"2022","unstructured":"Exuzides A, Reddy SR, Chang E, Ta JT, Patel AM, Paydar C, et al. Epidemiology of Huntington\u2019s disease in the United States medicare and medicaid populations. Neuroepidemiology. 2022;56(3):192\u2013200.","journal-title":"Neuroepidemiology"},{"key":"703_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RA Roos","year":"2010","unstructured":"Roos RA. Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"703_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40271-018-0312-x","volume":"11","author":"EM Thorley","year":"2018","unstructured":"Thorley EM, Iyer RG, Wicks P, Curran C, Gandhi SK, Abler V, et al. Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States. Patient. 2018;11(5):547\u201359.","journal-title":"Patient"},{"issue":"1","key":"703_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0891988719856697","volume":"33","author":"P Wibawa","year":"2020","unstructured":"Wibawa P, Zombor R, Dragovic M, Hayhow B, Lee J, Panegyres PK, et al. Anosognosia is associated with greater caregiver burden and poorer executive function in Huntington disease. J Geriatr Psychiatry Neurol. 2020;33(1):52\u20138.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"4","key":"703_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/arclin\/11.4.295","volume":"11","author":"AW Deckel","year":"1996","unstructured":"Deckel AW, Morrison D. Evidence of a neurologically based \u201cdenial of illness\u201d in patients with Huntington\u2019s disease. Arch Clin Neuropsychol. 1996;11(4):295\u2013302.","journal-title":"Arch Clin Neuropsychol"},{"key":"703_CR13","unstructured":"XENAZINE (tetrabenazine) [package insert]. Washington, DC: Prestwick Pharmaceuticals Inc."},{"key":"703_CR14","unstructured":"AUSTEDO (deutetrabenazine) [package Insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc."},{"key":"703_CR15","unstructured":"INGREZZA (valbenazine) [package insert]. San Diego, CA: Neurocrine Biosciences, Inc."},{"issue":"16","key":"703_CR16","doi-asserted-by":"publisher","first-page":"8363","DOI":"10.3390\/ijms22168363","volume":"22","author":"A Kim","year":"2021","unstructured":"Kim A, Lalonde K, Truesdell A, Gomes Welter P, Brocardo PS, Rosenstock TR, et al. New avenues for the treatment of Huntington\u2019s disease. Int J Mol Sci. 2021;22(16):8363.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"703_CR17","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/mds.25500","volume":"28","author":"R Reilmann","year":"2013","unstructured":"Reilmann R. Pharmacological treatment of chorea in Huntington\u2019s disease-good clinical practice versus evidence-based guideline. Mov Disord. 2013;28(8):1030\u20133.","journal-title":"Mov Disord"},{"key":"703_CR18","doi-asserted-by":"publisher","first-page":"Rrn1260","DOI":"10.1371\/currents.RRN1260","volume":"3","author":"JM Burgunder","year":"2011","unstructured":"Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington\u2019s disease. PLoS Curr. 2011;3:Rrn1260.","journal-title":"PLoS Curr"},{"issue":"1","key":"703_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mds.28855","volume":"37","author":"JJ Ferreira","year":"2022","unstructured":"Ferreira JJ, Rodrigues FB, Duarte GS, Mestre TA, Bachoud-Levi AC, Bentivoglio AR, et al. An MDS evidence-based review on treatments for Huntington\u2019s disease. Mov Disord. 2022;37(1):25\u201335.","journal-title":"Mov Disord"},{"issue":"6","key":"703_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(6):597\u2013603.","journal-title":"Neurology"},{"key":"703_CR21","doi-asserted-by":"crossref","unstructured":"Furr Stimming EE, Claassen DO, Farrar M, et al. Chorea characteristics and medication use in patients with Huntington Disease: data from Enroll-HD [poster]. Presented virtually at the 73rd Annual Meeting of the American Academy of Neurology; April 17\u201322. 2021.","DOI":"10.1212\/WNL.96.15_supplement.1530"},{"issue":"2","key":"703_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/mdc3.12571","volume":"5","author":"TA Mestre","year":"2018","unstructured":"Mestre TA, Forjaz MJ, Mahlknecht P, Cardoso F, Ferreira JJ, Reilmann R, et al. Rating scales for motor symptoms and signs in Huntington\u2019s disease: critique and recommendations. Mov Disord Clin Pract. 2018;5(2):111\u20137.","journal-title":"Mov Disord Clin Pract"},{"issue":"8","key":"703_CR23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","volume":"74","author":"S Frank","year":"2017","unstructured":"Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74(8):977\u201382.","journal-title":"JAMA Neurol"},{"issue":"1","key":"703_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"S Frank","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40\u201350.","journal-title":"JAMA"},{"issue":"2","key":"703_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/JHD-140109","volume":"3","author":"EJ Sitek","year":"2014","unstructured":"Sitek EJ, Thompson JC, Craufurd D, Snowden JS. Unawareness of deficits in Huntington\u2019s disease. J Huntingtons Dis. 2014;3(2):125\u201335.","journal-title":"J Huntingtons Dis"},{"issue":"suppl 1","key":"703_CR26","first-page":"296","volume":"37","author":"D Claassen","year":"2022","unstructured":"Claassen D, Romdhana H, Ayyagari R, et al. Real-world treatment patterns and outcomes in patients with chorea associated with Huntington disease using tetrabenazine or deutetrabenazine in combination with antipsychotic drugs. Mov Disord. 2022;37(suppl 1):296\u20137.","journal-title":"Mov Disord"},{"key":"703_CR27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201971","author":"D Claassen","year":"2023","unstructured":"Claassen D, Romdhana H, Ayyagari R, et al. Real-world effectiveness and safety of deutetrabenazine in combination with antipsychotic drugs in patients with chorea associated with Huntington disease. Neurology. 2023. https:\/\/doi.org\/10.1212\/WNL.0000000000201971.","journal-title":"Neurology"},{"key":"703_CR28","unstructured":"Furr Stimming EE, Claassen DO, Farrar M, et al. Characteristics and treatment patterns in patients with Huntington disease [poster]. Presented virtually at the Annual Meeting of the Huntington Study Group; October 29\u201331. 2020."},{"key":"703_CR29","unstructured":"Reshef S, Furr Stimming EE, Sung V et al. Relationship between Huntington\u2019s disease stage\/functional capacity and chorea severity using Enroll-HD data: a multiple regression analysis. Poster presented at 29th Annual Meeting of the Huntington Study Group (HSG); November 3\u20135, 2022; Tampa, Florida."},{"issue":"6","key":"703_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200200","volume":"13","author":"A Mendizabal","year":"2023","unstructured":"Mendizabal A, Singh AP, Perlman S, Brown A, Bordelon Y. Disparities in Huntington disease severity: analysis using the ENROLL-HD dataset. Neurol Clin Pract. 2023;13(6): e200200.","journal-title":"Neurol Clin Pract"}],"updated-by":[{"DOI":"10.1007\/s40120-025-00731-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000}}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00703-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00703-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00703-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T09:58:13Z","timestamp":1747648693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00703-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00703-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct two sentences.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40120-025-00731-z","URL":"https:\/\/doi.org\/10.1007\/s40120-025-00731-z","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Dietrich Haubenberger, Dr. Olga Klepitskaya, Dr. Sean C. Hinton, Ginny P. Sen, and Dr. Michael Serbin are full-time employees of Neurocrine Biosciences, Inc. Dr. Haubenberger receives publishing royalties from Oxford University Press. Hyunwoo Kim is a contract employee of Neurocrine Biosciences, Inc. Dr. Erin Furr Stimming receives research funding from CHDI, HDSA, Prilennia, University of Iowa\/NIH, UniQure, HSG\/NBI, and Sage Therapeutics, royalties from McGraw Hill and Oxford Publishing, and is a consultant\/application reviewer for Teva Pharmaceuticals and MJFF. Dr. Claassen has received research support from the NIH\/NINDS\/NIA\/NICHD\/NCCIH, Department of Defense, Griffin Family Foundation, and Huntington Disease Society of America; he has received pharmaceutical grant support from AbbVie, Alterity, Acadia, Biogen, BMS, Cerecour, Eli Lilly, Genentech-Roche, Lundbeck, Jazz Pharmaceuticals, Neurocrine, Teva Neuroscience, Wave Life Sciences, UniQure, and Vaccinex. He has received personal fees for consulting from Acadia, Alterity, Adamas, Anexon, Ceruvel, Lundbeck, Neurocrine, Spark, Uniqure, and Teva Neuroscience.The authors declare that there are no additional disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data used in this work were generously provided by participants in the Enroll-HD study and made available by CHDI Foundation, Inc. Enroll-HD is a global clinical research platform designed to facilitate clinical research in HD. Core datasets are collected annually from all research participants as part of this multi-center, longitudinal, observational study. Data are monitored for quality and accuracy using a risk-based monitoring approach. All sites are required to obtain and maintain local ethical approval and no additional approval was required for this analysis. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}